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Summary 
Virus-specific cytotoxic T lymphocytes (CTL) are involved in protective immunity to many virus 
infections.  It has recently been shown that CTL are detectable early during primary infection 
with  the primate lentiviruses,  human immunodeficiency virus  type  1  (HIV-1)  and  simian 
immunodeficiency  virus. To better characterize the CTL response during acute HIV-1 infection, 
HIV-l-specific CTL  clones  were generated from two patients during symptomatic HIV-1 
seroconversion.  These CTL clones demonstrated specificity for env of HIV-1 and recognized 
sequences within gp41. Two human histocompatibility leukocyte antigen (HLA) A31-restricted 
clones from the same individual were found to have differing virus strain specificities. Both dones 
recognized the 11-amino acid peptide RLRDLLLIVTR from position 770-780 of glYll. A change 
from T  to V at position 779 in this epitope abrogated lysis by one done but not the other. 
A  CTL clone from the other patient, restricted by a different class I HLA allele, recognized 
the nine-amino acid peptide HRLRDLLLI from position 769-777 of gp41. Of note, the peptide 
RLRDLLLIVTR has been shown by others to be presented to CTL by HLA-A3.1. Autologous 
virus sequences from seroconversion  and up to 15 wk after presentation in these two patients 
were recognized by the CTL clones isolated during acute infection. None of the CTL clones 
recognized the MN strain of HIV-1, indicating the problems inherent in relying on a single 
virus strain in the development of a vaccine. These studies have identified an immunodominant 
and promiscuous area for the generation of CTL responses within gp41.  This recognit/on of 
autologous virus sequences by the initial CTL response is consistent with the hypothesis that 
a single virus strain is transmitted to the seroconverter  and that the CTL response is involved 
in the initial control of that virus.  These studies indicate the importance of the CTL response 
to HIV-1 infection and have implications in the design of vaccines. 
cute infection with HIV-1 is characterized by fever, rash, 
and lymphadenopathy (1) in association with high levels 
of virus replication (2-4).  These high virus titers dramati- 
cally decline over the ensuing weeks, coinciding with the reso- 
lution of symptoms (2, 3). This suggests that an efficient 
immune response is present during the acute phase of infec- 
tion. Understanding the components of the immune system 
responsible for this early anti-HIV-1 response may be crucial 
for the design of effective vaccines. To this end, we have re- 
cently shown that the initial control of viremia is temporally 
associated with the presence of CD8 +, HIV-l-specific CTL 
that arise before neutralizing antibodies can be detected (Koup, 
R. A., J. T. Safrit, and D. D. Ho, unpublished observations). 
A  CTL response has also been reported in acute infection 
of rhesus  monkeys with  simian immunodeficiency virus 
(SIV) 1 and appears to coincide with clearance of viral  an- 
tigenemia (5). These results,  in concert with in vitro and 
in vivo data supporting the role of CTL in controlling virus 
infections (6-12),  suggest the importance of CTL in protec- 
tive immunity to HIV-1. To better define the role of CTL 
in acute HIV-1 infection, we sought to characterize the ini- 
tial CTL response to HIV-1 at the donal level. 
1 Abbreviations used in this palx,  r: aa, amino acid; B-LCL, B-lymphoblastoid 
cell line; SIV, simian immunodeficiency virus. 
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presented by class I molecules (13, 14). The aa sequence of 
peptides which bind to specific dass I HLA molecules is re- 
stricted, particularly at those residues that act as anchors in 
the binding of the peptide to the HLA (13-17). In addition, 
the position of a peptide epitope within a protein can deter- 
mine if that peptide is processed  and presented by a given 
class I HLA molecule (18), suggesting that flanking sequences 
can affect antigen processing for CTL recognition. Because 
of these sequence restrictions, and because HIV-1 undergoes 
natural sequence variation, particularly in the envelope gly- 
coprotein (19, 20), the virus may be able to escape the CTL 
response (21). In this report, we have therefore defined the 
minimum epitopes recognized by virus-specific CTL clones 
isolated during acute seroconversion,  and assessed the ability 
of autologous virus sequences to be recognized by these clones. 
These results help to define the initial immune response to 
HIV-1 infection, and have implications for vaccine design 
and models of viral pathogenesis. In addition, the results of 
these studies can be used to determine some of  the early events 
surrounding the transmission of HIV-1. 
Materials and Methods 
Patients.  Patients  L and F are two female sexual partners of 
HIV-l-infected men. Each presented during or shortly after acute 
seroconversion to HIV-1 with rash, fever, and lymphadenopathy. 
The virologic profiles of these two patients are covered in a sepa- 
rate publication (22). 
Cell  Lines.  EBV-transformed B-lymphoblastoid  cell lines 
(B-LCL) were established from PBMC by previously published 
methods (23). The dass I HLA type of each patient was deter- 
mined by Dr. Pablo Rubinstein at the New York Blood Center 
using standard serological typing methods. 
Recombinant Vaccinia Viruses.  Vaccinia  virus vectors  used in these 
studies included vAbT141, vAbT204, and vAbT299, which express 
gag, pol, and env genes of the BH10 clone of HIV-lnm, respectively 
(24). Serial nested deletions of the HIV-1Hm envelope gp160 were 
expressed in  vectors vAbT271, vAbT299, vAbT294, vAbT295, 
vAbT296, and vAbT364. The aa within gp160 which have been 
deleted from each vector are as follows (numbered according to 
LAI sequence  in Myers  et al. [19]): vAbT271, none; vAbT299, 42-60; 
vAbT294, 42-174; vAbT295, 42-287; vAbT296, 42-364; vAbT364, 
42-518. Vaccinia vectors expressing the complete envelope glyco- 
proteins of the RF (vAbT272 [25, 26]) and MN (MN462) strains 
of HIV-1 were also used  in some assays.  Vaccinia  virus strain  NYCBH 
served as a negative control in all experiments. 
Synthetic HIV-I Peptides.  Synthetic peptides corresponding to 
the HXB2 sequence of  HIV-1 envelope  were purchased  from Cam- 
bridge Research Biochemicals  (Wilmington, DE) and consisted of 
peptides 20 aa in hngth overlapping  by 10 aa. Other peptides were 
provided by Dr. Francis Ennis of the University of Massachusetts 
Medical Center (Worcester, MA) (40b--40e) or were synthesized 
by Dr. Y. K. Yip of the Public Health Research Institute (New 
York) (AD-1-AD-7, AD-13, and AD-14). All peptides were recon- 
stituted to 2 mg/ral in 10% DMSO (Sigma  Chemical  Co., St. Louis, 
MO) and 1 mM dithiothreitol (Sigma  Chemical  Co.). Peptides  were 
used at 100/~g/ml final concentration to coat target cells for CTb 
mediated lysis. 
Isolation of HIV-l-specific CTL Clones.  CTL clones specific  for 
HIV-1 antigens were isolated  by previously  published methods (27). 
Briefly,  FicolI-Hypaque-isohted  PBMC from each  patient were in- 
cubated at 10, 25, and 50 cells per well in 96-well tissue culture 
phtes with 10  s -pirradiated (3,000 rad) allogeneic PBMC and 0.1 
/zg/ml of the anti-CD3 mAb 12F6 (28) in RPMI 1640 (BioWhit- 
taker, WalkersviUe,  MD) supplemented  with 10% heat-inactivated 
FCS and 100 U/ml of recombinant human IL-2 (R10/100). Cells 
from wells demonstrating growth after 3-4 wk were stimulated 
with fresh feeder cells, 12F6, and IL-2, and expanded into 24-well 
tissue culture plates. Cells from these wells were screened 2 wk 
hter for HIV-l-specific  lytic activity against autologous B-LCL  in- 
fected  with vaccinia  vectors expressing  HW-lgag, pol, and env (IIIB, 
R.F, and MN) proteins in nCr-release assays. Cells from wells that 
demonstrated  HIV-l-specific  lyric  activity  were fed every  3-4 d with 
fresh R10/100 and restimulated every 2-3 wk with 12F6 and ir- 
radiated feeders. 
Cytotoxicity  Assays.  All CTL assays were conventional 5-h 
S*Cr-release assays  as previously  described (29, 30). Briefly,  B-LCL 
were infected with appropriate vacdnia virus vectors and labeled 
for 16 h with 100 #Ci NazSlCrO4 (New England Nuclear, Boston, 
MA). These target  ceils were then washed thrice in PBS and 
resuspended in ILPMI 1640 supplemented with 10% FCS (R10) 
at 10  s cells/ml. For peptide assays, the B-LCL were labeled for 16 h 
with Na2nCrO4, washed once in R10, and incubated for 1.5 h 
with 100 gg/ml of the appropriate peptide in 300/A of ILl0. These 
cells were then washed three times to remove unbound peptide 
and resuspended as above. Target ceils at 104 per well were ali- 
quotted into wells of 96-weil U-bottom plates containing various 
concentrations of effector cells. E/T were g10:1. In some experi- 
ments, mAbs were used to inhibit class I or II HLA-restricted cy- 
totoxicity as previously described (29). After 5 h at 37~  100 gl 
of supernatant was harvested from each well and the radioactivity 
was determined in a y-counter (Wallach  Wizzard; Pharmacia  LKB, 
Gaithersburg, MD). Percent cytotoxidty  was calculated  according 
to the following formula: 100x (experimental release -  sponta- 
neous release)/(total release -  spontaneous release). Spontaneous 
release was measured from target cells in the presence of media 
alone and total release was taken as the amount of radioactivity 
in one half the volume of target cells originally aliquoted into the 
wells. Spontaneous release for these assays  was always  <30%.  All 
assays were performed in triplicate. 
Autologous Virus Sequencing.  Autologous virus from each pa- 
tient was sequenced  as previously  described (22). Briefly,  DNA iso- 
lated from PBMC was used in nested PCR to amplify sequences 
in gp41 of env. The following primers were used: gp41/nef outer 
set P31 (7695-7727 according to the pNL4-3 sequence in the Los 
Alamos  Database; 5'-TAGGAGTAGCACCCACCAAGC~AA- 
AGAGAAGAG-Y) and P18  (9163-9132; 5'-TTCTGCCAATCA- 
GGGAAGTAGCCTTGTGTGTG-3'), gp41/nef  inner  set  P32 
(8322-8348; 5'-CTAT GTGAATTCAGTTAGC~AGGGAT-Y)  and 
P16 (9028-8999; 5'-TAAGTCAT'IGGTCTAGAAGGTACCTGA- 
GGT-3'). PCR products  were digested  with EcoRI and XbaI, ligeted 
to M13m191LF,  and transfected  into JM103 cells. Single  strand DNA 
was then sequenced using Sequenase 2.0 kits (United States Bio- 
chemical Corp., Cleveland, OH) according to the manufacturer's 
directions. 8-11 clones were sequenced from each time point for 
each patient. 
Results 
Isolation of CTL Clones.  HIV-specific CTL lines from pa- 
tients L and F were isolated from PBMC by limiting dilu- 
tion. The PBMC samples came from day 19 after presenta- 
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F. In total, 10 env-, 3 gag-, and 3 pol-spedfic CTL lines were 
isohted from these two patients.  We further characterized 
two env-specific  CTL lines from each patient. Each CTL line 
recognized and lysed the autolognus B-LCL expressing env 
of HIV-I,m as seen in Fig.  1. CTL lines 1E and 2E from 
patient L both lysed autologous B-LCL expressing env se- 
quences from IIIB and RF strains of HIV-1. CTL line 2E 
also recognized  ent,  of HIV-I~  whereas line  1E did not 
(Fig. 1 A). Line 3B1 from patient F also recognized env from 
IIIB and ILF but not MN strains of  HIV-1, whereas line R2D3 
only recognized IIIB env. 
The differential recognition of IIIB and RF env by CTL 
lines R2D3 and 3B1 was further characterized. As each CTL 
line was isolated from wells containing 10 ceils each, it is 
possible that neither is truly tonal. To determine if a dis- 
crepancy in recognition of IIIB and RF env sequences existed 
between lines R2D3  and 3B1, cytolysis was measured  at 
varying E/T ratios  (Fig. 2). Whereas line 3B1 recognized 
and lysed IIIB  and ILF env-expressing targets  with equal 
efficiency at  all ratios,  line  R2D3  failed to  lyse RF  env- 
expressing targets even at ratios where there was effident rec- 
ognition and lysis of IIIB env-expressing  targets. These results 
indicate that these two CTL lines are functionally donal and 
differ exquisitely in recognition of RP env sequences. Based 
upon these results and the fact that R2D3, 3B1, 1E, and 2E 
were maintained in culture for >1 yr without changes in 
specificity, they are hereafter referred to as "clones". 
HLA Restriction.  Each of the tones isolated from the pa- 
tients were found to be CD8 + and CD4-  by flow cytom- 
etry (data not shown). AUogeneic B-LCL matched to the pa- 
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Figure 1.  HIV-1 env specificity of CTL isolated from seroconverting 
patients. CTL lines were isolated from patient L (.4) and patient F (B) 
19 and 13 d, respectively, after presenting with symptoms of acute HIV-1 
infection.  CTL were tested at an E/T ratio of 10:1 against autologous 
B-I.CL infected with control vaccinia virus strain NYCBH (VAC, D), 
or HIV-l-expressing  vaccinia virus vectors vAbT141  (GAG, B), vAbT204 
(POL, []), vAbT299  (ENV-IIIB, []), vAbT272  (ENV-RF, 8~), and MN462 
(ENV-MN,  I). 
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Figure 2.  Recognition  of IIIB and ILF env by R2D3 and 3B1 at varying 
E/T ratios. CTL lines R2D3 (.4) and 3B1 (B) were tested for lysis ofau- 
toiogous B-LCL infected with control vaccinia  virus strain NYCBH (VAC, 
O), or HIV-l-expressing vaccinia virus vectors vAbT271 (ENV-IIIB, D) 
and vAbT272 (ENV-KF, A) at E/T ratios from 5:1 to 0.04:1. 
tients at only one class I HLA allde were used to determine 
the class I HLA restriction of the individual clones. Clones 
R2D3 and 3B1 both recognized HIV-1 env in association 
with the HLA-A31 molecttle, whereas done 2E from patient 
L was restricted by HLA-A32 (Table 1). The class I HLA 
restriction for done 1E could not be determined (Table 1) 
despite the use of eight different B-LCL matched at HLA-A2 
(including .IY-LCL, which  expresses HLA-A2.1),  three 
matched at HLA-A32, five  matched at HLA-B18, and two 
matched at HLA-B51 (data not shown). In addition, the above 
B-LCL express all known HLA-C loci except for Cwl. The 
class I HLA type of patient L was confirmed with a freshly 
isolated sample by a separate HLA typing laboratory. Cytol- 
)'sis by done 1E was inhibited by a mAb directed against 
VAC 
ENV-IIIB 
ENV-IIIB + W632~ 
ENV-IIIB + HB-180 
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Figure 3.  Inh'bition of clone 1E em,-specific  lysis by mAbs to class I 
and II HLA. Lysis of autologous B-LCL infected with vAbT299 (ENV- 
IIIB) in the presence or absence of mAbs against class I I-ILA (W6J2) 
or chss II HLA (HB-180)  was tested at an E/T ratio of 5:1. Autologous 
B-I.CL infected  with NYCBH (VAC)  served  as a control for env-$pecifac  lysis. 
465  Safrit et al. Table  1.  HLA Restriction of CTL Clones 
CTL clone 
R2D3  3B1 
VAC  ENV  VAC  ENV 
Target HLA match* 
Autologous  3t  74  0  46 
(A24, A31, B18, Bw60, Cw3) 
A24  1  7  2  2 
A31  3  75  5  37 
B18  3  4  0  0 
Bw60  2  6  0  0 
Cw3  2  4  0  1 
1E  2E 
Target  I-ILA match 
Autologous  4  53  9  45 
(A2, ~2,  B18, B51) 
A2  ND  9  ND  4 
A32  1  1  4  26 
B18  0  0  0  6 
B51  0  4  0  5 
* Autologous B-LCL or B-LCL matched to the CTL clones at  single class I  alleles were used. 
t Vaccinia virus vectors used to infect B-LCL were NYCBH (VAC) and vAbT299 (ENV). Results are expressed as percent  spedfic lysis at an E/T 
ratio of 10:1. 
common determinants on class I HLA (W632) but not by 
an antibody to class II HLA (HB-180) indicating that clone 
1E is class I HLA restricted (Fig.  3). The B-I.CL from pa- 
tient L was found to express HLA-A2.1 by isodectric focussing 
and by its ability to present an HLA-A2.1-restricted influenza 
matrix peptide to an HLA-A2.1-restricted CTL clone, ruling 
out the possibility that a minor HLA-A2 variant was respon- 
sible for the inability to map the HLA restriction of clone 
1E (McMichael, Andrew J., personal communication). It is 
therefore likely that this clone is restricted by a minor sub- 
type of one of the other known HLA serotypes. 
EpiWpe Localization with Vaccinia Vectors Expressing Truncated 
Envelope Genes.  Autologous B-LCL infected with a series 
of vaccinia vectors expressing truncations of the envelope gene 
vAbT 271 
(BH10) 
vAbT 299 
(A42-60) 
vAbT 294 
(&42-174) 
vAbT 295 
(A42-287) 
vAbT 296 
(&42-364) 
vAbT 364 
(A42-518) 
HIV-1 Envelomm Truncation:  % S  Devlflc Lvsis bv Clone: 
IE  2E  R2D3  3131 
VAC  1  0  1  0 
........  ~  53  45  56  81 
--  --  .--  ~  -  t  56  41  68  75 
K~....,.......~--  ￿9  i  =  57  35  64  73 
I~.~.~.,..,.~--  ~  -  i  56  40  60  88 
....  54  39  63  67 
i  ~  28  35  54  68 
Imgl  gpl~  I  gp41  I 
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Figure 4.  Localization of the re- 
gion of HIV-1 eat, recognized by the 
CTL clones. Vaccinia virus vectors 
expressing nested ddetions of the 
HIV-lm env gene were used to in- 
fect autologous  B-LCL and  tested 
for ly=s by CTL clones R2D3, 3B1, 
1E, and 2E at an E/T ratio of 10:1. 
The amino acid positions  affected 
by the era, deletions for.each expres- 
sion vector is given  in pamatheses. 
Vaa~aia  virus strain  NY~H (VAC) 
was used as a control. (Sl~ated areas) 
Hypercariable  regions  of  HIV-1 
gp120. (Sig) Signal peptide region 
of HIV-1 env. were used to determine the region of the HIV-1 envelope 
protein recognized by these clones. Clones R2D3, 3B1, 1E, 
and 2E each recognized and lysed autologous B-LCL infected 
with vectors expressing only the signal peptide and gp41 (Fig. 
4). The epitope recognized by these clones was therefore local- 
ized to either the signal peptide (aa 1-42) or gp41 (aa518-856). 
Fine Epitope Mafrping with Overlapping  Peptides.  Autologous 
B-LCL  were incubated  with  overlapping  peptides  corre- 
sponding to sequences within the signal peptide or gp41 to 
further define the specific  epitopes recognized by these clones. 
By this method, HLA-A31-restricted clones R2D3 and 3B1 
from patient F and clone 1E from patient L recognized the 
same peptide (e77) spanning  aa 761-780  of gp41 (Fig. 5). 
The HLA-A32-restricted clone 2E from patient L was specific 
for peptide e71 spanning aa 701-720 of gp41 (Fig. 5). Thus 
the epitopes recognized by clones R2D3,  3B1, and 1E lie 
within the 20-aa sequence RSLCLFSYHtLLtLDLLLIVTtL, 
whereas the epitope recognized by clone 2E is contained within 
the aa sequence VLSIVNRVRQGYSPLSFQTH. 
Serial amino and carboxy truncations of the above 20-aa 
peptides were used to map the minimum epitope for clones 
R2D3, 3B1, and 1E, which were specific for the same 20-aa 
peptide e77.  The minimum epitope  recognized by HLA- 
A31-restricted clones R2D3 and 3B1 was determined to be 
the 11-aa sequence tLLRDLLLIVTR (Table 2). Removal of 
the single arginine from either end of this peptide abrogated 
lysis by these clones. Similarly,  the minimum epitope for HLA- 
A32-restricted done 1E was determined to be the nine-aa 
sequence HtLLRDLLLI (Table 2). Thus, the epitopes recog- 
nized by these three clones from two different subjects, re- 
stricted by two different HLA molecules, overlap by eight 
amino adds. The overlap region (tLLtLDLLLI)  is insut~dent, 
however, for recognition by any of these clones. 
Recognition of Distinct Viral Envelope Proteins.  As shown 
in Figs. 1 and 2, clones R2D3, 3B1, and 1E have subtle differ- 
ences in their specificity allowing the recognition of different 
viral strains. This specificity  difference  is especially  intriguing 
when comparing clones R2D3 and 3B1 from patient F. Clone 
3B1 recognizes gp41 from the IIIB and tLF but not MN strains 
of HIV-1, whereas done K2D3 only recognizes gp41 from 
IIIB. The aa sequences  for IIIK RF, and MN strains of HIV-1 
within the minimum epitope recognized by P,2D3, 3B1, and 
1E are shown in Table 3. A single nonconservative valine for 
threonine change in the RF sequence at position  10 of the 
R2D3 and 3B1 epitope does not affect recognition by clone 
3B1 whereas it abrogates recognition by clone P,2D3 (Table 
3). No aa differences  between IIIB and RF virus strains were 
apparent in the 1E epitope. Finally, multiple aa changes and 
deletions were apparent between the IIIB and MN virus strains 
within the minimum epitopes recognized by R2D3,  3B1, 
and 1E. 
Recognition of  Autologous Viral  Sequences  Autologous virus 
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Figure 5.  Localization  of  the region  of gp41 recognized  by the CTL clones  by use of overhpping  peptides. Serial  peptides ,,o20 aa in length, overlap- 
ping by 10 aa, and cor'zesponding  to the entire signal  ix-pride  and gp41 regions  of HIV-lm wes'e  used to sensitize  aumlogous  B-LCL for lysis  by CTL 
clones R2D3, 3B1, 11/, and 2E at an E/T ratio of 10:1. Autologous  B-LCL infected  with NYCBH (VAC)  and vAbT299 (ENV) were  used as controls. 
The aa numbers corresponding  to the sequence  of HIV-lm for each peptide are given on the y-axis. 
467  Safrit et al. Table  2.  Minimum Epitope Determination of CTL Clones R2D3,  3B1, and 1E 
Peptide  Sequence 
Percent specific lysis by clone 
R2D3  3B1  1E 
e76" 
e77 
e78 
AD-1 
AD-2 
AD-3 
AD-4 
AD-5 
AD-6 
AD-13 
AD-14 
40b 
40c 
40d 
40e 
AD-7 
GSLALIWDDLRSLCLFSYHR* 
RSLCLFSYHRLRDLLLIVTR 
LRDLLLIVTRIVELLGRRGW 
LCLFSYHRLRDLLLIVTR 
LFSYHRLRDLLLIVTR 
SYHRLRDLLLIVTR 
RSLCLFSYHRLRDLLLIV 
RSLCLFSYHRLRDLLL 
RSLCLFSYHRLRDL 
YHRLRDLLLIV 
YHRLRDLLLI 
HRLRDLLLIVTR 
RLRDLLLIVTR 
LRDLLLIVTR 
RDLLLIVTR 
RLRDLLLIVT 
2  6  3 
59  89  41 
1  6  3 
35  74  48 
88  86  72 
69  92  72 
0  1  76 
2  6  5 
0  8  3 
1  10  74 
1  9  77 
37  82  56 
26  70  2 
2  2  1 
0  4  2 
0  0  0 
" Peptide designations are as used elsewhere in this and other publications. 
* Single letter designations of aa are used. Sequences correspond to HXB2 clone of HIV-1. 
$ Assays were performed at an E/T ratio of 10:1. 
sequences  within  gp41  were  determined for  each  patient 
13-19 d  after presentation and 92-102 d  hence.  As seen in 
Hg. 6, the sequence of each patient's autologous virus was 
identical to the IIIB sequence within the minimum epitope 
in 8-11 dones sequenced from the early and later time points. 
As it has been noted that surrounding aa can affect processing 
and presentation  of peptide epitopes  by class I HLA mole- 
cules (18),  the aa sequences of the regions immediately be- 
fore  and after the defined  epitopes  were also  determined. 
Whereas a homogeneous virus population was present within 
the PBMC  of each patient  (22),  some sequence  variation 
leading to aa changes were noted (Fig. 6). Within the region 
Table  3.  Comparison  of HIV-1 11113, RF, and MN Envelope Sequences within the Minimum Epitopes of CTL Clones R2D3, 3BI, and 1E 
Patient  Clone  Peptide epitope  Strain  Percent specific lysis 
F  R2D3  RLRDLLL I VTR*  IIIB  67t 
.........  V.  RF  5 
H- H ......  AA.  MN  0 
F  3B1  RLRDLLL I VTR  IIIB  65 
.........  V.  RF  65 
H- H ......  AA.  MN  0 
L  1E  HRLRDLLL I  IIIB  50 
.........  EF  25 
YH - H ......  MN  0 
" Single letter designations of aa are used. The aa sequence for HXB2 clone of HIV-lmB is given. Dots indicate aa homology, dashes indicate aa 
deletions in comparison to the HXB2  sequence. 
* Assays were performed at an E/T ratio of 10:1. 
468  HIV-l-spedfic Cytotoxic T Lymphocyte Clones in Acute Inf~tion Figure 6.  Comparison of the aa sequences  of autologous virus and HIV- 
IlIIB in the area of gp41 recognized by CTL clones R2D3, 3B1, and 1E. 
Deduced aa sequences  in gp41 are shown for viruses present within PBMC 
on the same day as the CTL clones were isolated and from 102 or 92 d 
after presentation, for patients L and F. The enact region of CTL recogni- 
tion and the immediate surrounding  regions are shown. Single letter desig- 
nations of aa are used. (Dots) aa homology with the HIV-lnm sequence. 
(Shaded boxes) minimum  epitopes recognized by CTL clones R2D3, 3B1, 
and 1E. (Right) The fraction of virus clones with the given sequence over 
the total number of clones sequenced. 
containing and surrounding the epitopes defined by R2D3, 
3B1, and 1E, no differences were noted between the deduced 
aa sequences of autologous viruses  and the aa sequence of 
the IIIB strain of HIV-1 (Fig. 6). This indicates  that all of 
the autologous viral sequences in these two patients during 
and up to 15 wk after presentation are recognized by the CTL 
clones  present at the time of seroconversion. 
Discussion 
We and others (2--4) have previously shown that there is 
a rapid decline in viremia during acute seroconversion. Based 
on observations in SIV-infected rhesus macaques, it has been 
postulated that CTL are involved in the early control of viremia 
(5). To demonstrate the relationship between the CTL re- 
sponse and viruses present in acutely infected patients, we 
have isolated and characterized  four CTL clones from two 
patients during acute seroconversion. 
Three of the four clones characterized in this study recog- 
nize overlapping epitopes spanning aa 769-780 of gp41. The 
recognition of overlapping epitopes by HIV-l-specific CTL 
clones from different patients has been previously reported. 
Two groups have identified CTL clones restricted by HLA- 
BS, HLA-B14 (31, 32),  and HLA-A24 (33) that recognize 
epitopes within aa 582-591 of gp41. Overlapping epitopes, 
restricted by varying dass  I  HLA  nudes,  have  also  been 
identified within HIV-1 gag (21, 31, 34).  A  CTL epitope 
within gp41 recently identified by Takahashi et al. (35) is ex- 
actly the same as the epitope recognized by clones R2D3 and 
3B1. Whereas R2D3 and 3B1 are HLA-A31 restricted, the 
Takahashi E7.20 CTL done that recognizes this epitope is 
HLA-A3.1 restricted. Clone 1E, which is restricted by an- 
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other class I HLA molecule, recognizes a nine-aa  sequence 
offset from the above epitope by one aa. Whereas the class 
I HLA molecule that presents the peptide to CTL clone 1E 
is undefined, it is not HLA-A31 or HLA-A3.1 as neither 
of these HLA alleles is expressed by patient L from whom 
the clone was isolated,  and B-LCLs expressing these HLA 
alleles fail to present the peptide to clone 1E. Thus, within 
the 12-an sequence HRLRDLLLIVTR are CTL epitopes pre- 
sented by three distinct class I HLA molecules. 
"Promiscuous" class II HLA epitopes, capable  of being 
presented by multiple class II HLA molecules, have been de- 
scribed  (36, 37).  A  similar promiscuity of class I HLA-re- 
strieted epitopes, however, has seldom been noted (38). This 
probably relates to the more su'ingent requirements for pep- 
tide binding to class I HLA molecules than to dass II HLA 
molecules (15, 39-42). The identification here of  HLA-A31-re- 
stricted dones R2D3 and 3B1, which recognize the same 
11-an stretch of gp41 as the HLA-A3.1-restricted done E7.20 
(35), indicates that at least some degree of  promiscuity is pos- 
sible within class I HLA-restricted epitopes. 
The fine specificity differences between CTL clones is ex- 
emplified by clones R2D3 and 3B1. Both clones were iso- 
lated from the same patient, are restricted by the same class 
I HLA molecule, and recognize the same minimum epitope. 
Clone 3B1 can recognize a valine for threonine nonconserva- 
tire change present in the RB virus sequence, yet this change 
cannot be recognized by done R2D3. This indicates that the 
inability of R2D3 to recognize the RF virus sequence is a 
property of the CTL clone and does not represent the in- 
ability of the RP sequence to be properly processed or presented 
by HLA-A31. It is therefore apparent that a nonconservative 
valine to threonine change at position 10 of the epitope defined 
by done 3B1 does not affect binding of the peptide to the 
HLA-A31 molecule, suggesting that position 10 is not an 
anchor position in the HLA-A31 motif. 
The fact that clones R2D3 and 3B1 exhibit differing abili- 
ties to recognize the RF virus sequence within the HLA- 
A31-restricted epitope suggests that different TCR gene rear- 
rangements are used by these clones (Table 3). Thus, during 
acute seroconversion in this patient, more than one TCIL gene 
rearrangement was used in the CTL response to this HLA- 
A31-restricted epitope. This suggests that the CTL response 
to individual viral epitopes during primary HIV-1 infection 
might be redundant. This could theoretically result in a cd- 
lular response more eftident in controlling the early high levels 
of viremia and more capable of responding to aa variations 
within a given epitope, than if only a single donal response 
were generated. 
The identification of this region of gp41 as immunodomi- 
nant for the generation of CTL responses may result because 
the sequence is highly conserved among North American and 
European isolates of HIV-1 (19). In contrast, the MN strain 
of HIV-1 has multiple aa changes and ddetions in this re- 
gion (unusual among North American and European iso- 
lates), and it is not recognized by dories R2D3, 3B1, 1E (Table 
3), or E7.20 (35).  Therefore, vaccines based upon the MN 
strain of HIV-1 would not be appropriate for eliciting this 
particular CTL response. In addition, our results do not ex- dude the possibility that additional clones specific for vari- 
able regions of HIV-1 might be present during acute serocon- 
version, but are unable to be measured within the constraints 
of the vaccinia vector system that  we use. 
The ability of CTL clones isolated during acute serocon- 
version to recognize autologous virus is consistent with the 
hypothesis that the CTL response is necessary for the early 
control of viremia. In this report, we have shown that three 
CTL clones isolated during acute seroconversion are able to 
recognize autologous virus sequences recovered both during 
the acute phase of infection and 3-4 mo hter. This recogni- 
tion of autologous viral sequences by the initial CTL response 
is relevant to our understanding  of virus transmission  and 
hinges on two possible scenarios.  First,  it has been shown 
that the virus population in early infection is extremely ho- 
mogeneous, because in most transmissions,  an unknown sdec- 
tive mechanism allows only a single virus species to be trans- 
mitted (22, 43). If this were the case, then one would predict 
that the initial CTL response, directed at the transmitted virus, 
would lead to control of the original viremia. Alternatively, 
others have shown (44) that more than one virus species may 
be transmitted to a patient, and that the virus present after 
the initial burst of viremia represents a minor variant of the 
viruses present within the virus donor (22). Therefore, one 
could hypothesize that multiple viruses are transmitted but 
only one virus species (presumably one that escapes the ini- 
tial immune response) is then sdectively amplified to create 
the homogeneous population identified within seroconverters. 
Assuming that the CTL response is involved in the control 
in viremia, one would expect the early CTL response to fail 
to recognize most autologous virus strains if this model of 
transmission were correct. Our present results showing CTL 
recognition of autologous virus and subsequent control of 
viremia in  these patients  favor the former hypothesis. 
HIV-1 variability can develop very quickly after acute in- 
fection (22,  45).  It has  been proposed that  this  variability 
can allow HIV-1 to escape the CTL response of the host (21). 
Although  we have noted some virus variability occurring 
during the first 15 wk of infection in the two patients presented 
here (Fig. 6), we have yet to identify any virus strains that 
would be capable of escaping the CTL clones isolated during 
the acute phase of infection.  This is consistent with what 
has been observed in SIV infection of rhesus monkeys (46). 
Longer follow-up of these patients will be required to deter- 
mine if viruses ultimately emerge which are able to escape 
recognition  by the initial  CTL response. 
In summary,  we have characterized  CTL clones isolated 
from two seroconverting patients in order to define the pos- 
sible role of the CTL response in early HIV-1 infection. Our 
results indicate that the CTL response is present very early 
in infection and the viruses associated with the initial burst 
in  viremia  are recognized  by CTL  clones isolated during 
seroconversion. Whereas virus variation begins early in in- 
fection, we have yet to identify viruses able to escape the ini- 
tial CTL response in these two patients.  These results em- 
phasize the possible role of CTL in protective immunity to 
HIV-1 infection and establish the rationale for stimulating 
such a response in vaccine strategies. 
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